Table 4 Association between the changes of putative CSC population after PST and clinicopathologic characteristics of the tumours in the post-chemotherapy specimens
CD44+/CD24− tumour cell proportion | ALDH1 grade | |||||
|---|---|---|---|---|---|---|
Characteristics | No change or decrease (no. (%)) | Increase (no. (%)) | P -value a | No change or decrease (no. (%)) | Increase (no. (%)) | P -value a |
ypT stage | 0.091 | 0.185 | ||||
T0–2 (79) | 50 (91) | 29 (78) | 71 (88) | 8 (73) | ||
T3–4 (13) | 5 (9) | 8 (22) | 10 (12) | 3 (27) | ||
ypN stage | 0.267 | 0.745 | ||||
N0 (31) | 21 (38) | 10 (27) | 28 (35) | 3 (27) | ||
N1–3 (61) | 34 (62) | 27 (73) | 53 (65) | 8 (73) | ||
Oestrogen receptor b | 0.067 | 0.017 | ||||
Negative (30) | 12 (29) | 18 (49) | 22 (32) | 8 (73) | ||
Positive (49) | 30 (71) | 19 (51) | 46 (68) | 3 (27) | ||
HER2 c | 0.933 | 0.150 | ||||
Negative (58) | 31 (74) | 27 (73) | 52 (77) | 6 (55) | ||
Positive (21) | 11 (26) | 10 (27) | 16 (23) | 5 (45) | ||
Ki-67 labelling index | 0.038 | 0.311 | ||||
⩽20% (54) | 33 (79) | 21 (57) | 48 (71) | 6 (55) | ||
>20% (25) | 9 (21) | 16 (43) | 20 (29) | 5 (45) | ||
P53 staining | 0.575 | 0.030 | ||||
Negative (64) | 35 (83) | 29 (78) | 58 (85) | 6 (55) | ||
Positive (15) | 7 (17) | 8 (22) | 10 (15) | 5 (45) | ||
